Safety Study of CTS21166 to Treat Alzheimer Disease

Completed · Phase 1 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

This study is the first human exposure for the drug candidate CTS21166 in healthy male volunteers

Key facts

Study ID

NCT00621010

Run by

CoMentis

People needed

56

Starts

2007-06-01

Expected to finish

2008-02-01

Last updated by the study team

2008-07-09

Who can join

Age: 22 and older. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Healthy adult male > age 21;
• non-smoker (minimum 6 months);

You may not qualify if…

• History or evidence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,neurologic, psychiatric, oncologic, or allergic (including anaphylactic drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease
• History or evidence of intravenous illicit drug use, human immunodeficiency virus (HIV), hepatitis B, or hepatitis C;
• Participation in another clinical trial within 30 days prior to dosing

Where it is running

• Lifetree Clinical Research — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.